Review article · 2024 · Open access
CAR immunotherapy in autoimmune diseases: promises and challenges
Frontiers in Immunology, 15, 1461102 · Published 1 October 2024 · DOI 10.3389/fimmu.2024.1461102
In brief
“CAR immunotherapy in autoimmune diseases: promises and challenges” is a 2024 review article by Jingjing Yu and 5 co-authors, published in Frontiers in Immunology. OpenAlex counts 39 citations as of 21 November 2026. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.
- Citations
- 39
- Most cited in
- 2025 (19)
- Field-weighted impact
- 1.74
- References
- 66
- Authors
- 6
Abstract
In recent years, the use of chimeric antigen receptor (CAR)-T cells has emerged as a promising immunotherapy in multiple diseases. CAR-T cells are T cells genetically modified to express a surface receptor, known as CAR, for the targeting of cognate antigens on specific cells. The effectiveness of CAR-T cell therapy in hematologic malignancies including leukemia, myeloma, and non-Hodgkin's lymphoma has led to consider its use as a potential avenue of treatment for autoimmune diseases. However, broadening the use of CAR-T cell therapy to a large spectrum of autoimmune conditions is challenging particularly because of the possible development of side effects including cytokine release syndrome and neurotoxicity. The design of CAR therapy that include additional immune cells such as double-negative T cells, γδ T cells, T regulatory cells and natural killer cells has shown promising results in preclinical studies and clinical trials in oncology, suggesting a similar potential utility in the treatment of autoimmune diseases. This review examines the mechanisms, efficacy, and safety of CAR approaches with a focus on their use in autoimmune diseases including systemic lupus erythematosus, Sjögren's syndrome, systemic sclerosis, multiple sclerosis, myasthenia gravis, lupus nephritis and other autoimmune diseases. Advantages and disadvantages as compared to CAR-T cell therapy will also be discussed.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Yu, J., Yang, Y., Gu, Z., Shi, M., La Cava, A., & Liu, A. (2024). CAR immunotherapy in autoimmune diseases: promises and challenges. Frontiers in Immunology, 15, 1461102. https://doi.org/10.3389/fimmu.2024.1461102
MLA 9
Yu, Jingjing, et al. “CAR immunotherapy in autoimmune diseases: promises and challenges.” Frontiers in Immunology, vol. 15, 2024, p. 1461102. https://doi.org/10.3389/fimmu.2024.1461102.
Chicago
Yu, Jingjing, Yi Yang, Zhanjing Gu, Min Shi, Antonio La Cava, and Aijing Liu. 2024. “CAR immunotherapy in autoimmune diseases: promises and challenges.” Frontiers in Immunology 15: 1461102. https://doi.org/10.3389/fimmu.2024.1461102.
Harvard
Yu, J. et al. (2024) ‘CAR immunotherapy in autoimmune diseases: promises and challenges’, Frontiers in Immunology, 15, p. 1461102. doi:10.3389/fimmu.2024.1461102.
IEEE
J. Yu, Y. Yang, Z. Gu, M. Shi, A. La Cava, and A. Liu, “CAR immunotherapy in autoimmune diseases: promises and challenges,” Frontiers in Immunology, vol. 15, p. 1461102, 2024, doi: 10.3389/fimmu.2024.1461102.
BibTeX
@article{yu2024immunotherapy,
title = {{CAR immunotherapy in autoimmune diseases: promises and challenges}},
author = {Yu, Jingjing and Yang, Yi and Gu, Zhanjing and Shi, Min and La Cava, Antonio and Liu, Aijing},
journal = {Frontiers in Immunology},
year = {2024},
volume = {15},
pages = {1461102},
doi = {10.3389/fimmu.2024.1461102},
url = {https://doi.org/10.3389/fimmu.2024.1461102}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2024 | 1 | |
| 2025 | 19 | |
| 2026 | 19 |
Its field-weighted citation impact is 1.74: it has been cited 1.74 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- chimeric antigen receptor
- CAR T-cell therapy
- autoimmune disease
- cytokine release syndrome
- neurotoxicity
- double-negative T cells
- γδ T cells
- regulatory T cells
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Yu, J., Yang, Y., Gu, Z., Shi, M., La Cava, A., & Liu, A. (2024). CAR immunotherapy in autoimmune diseases: promises and challenges. Frontiers in Immunology, 15, 1461102. https://doi.org/10.3389/fimmu.2024.1461102
How many times has this paper been cited?
39 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.
Who wrote this paper?
Jingjing Yu, Yi Yang, Zhanjing Gu, Min Shi, Antonio La Cava, Aijing Liu.
What is the DOI of this paper?
10.3389/fimmu.2024.1461102, permanently at https://doi.org/10.3389/fimmu.2024.1461102. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.